Across TCGA pan-cancer cohorts, HIGD2A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HIGD2A data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HIGD2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HIGD2A expression acts as an unfavorable survival marker.
BLCA are the cancer types where HIGD2A Mutation most reproducibly stratifies survival.